Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings
EP Europace, doi:10.1093/europace/euaa216
The aim of the study was to describe ECG modifications and arrhythmic events in COVID-19 patients undergoing hydroxychloroquine (HCQ) therapy in different clinical settings.
Conclusion HCQ administration, alone or in combination with other potentially QTc-prolonging drugs, proved safe for a short-term treatment of patients with COVID-19 infection, causing only modest QTc prolongation. Serial ECG recordings at 36-72 h and later than 96 h from treatment onset can detect QTc changes that might suggest therapy modification. This experience provides a framework to enable HCQ therapy implementation in different clinical settings for future efficacy trials.
Supplementary material Supplementary material is available at Europace online. Conflict of interest: Dr. A.S. own stocks from Gilead Science inc. The rest of authors declare no conflict of interest.
Ben-Zvi, Kivity, Langevitz, Shoenfeld, Hydroxychloroquine: from malaria to autoimmunity, Clin Rev Allergy Immunol
Bessie `re, Roccia, Delinie `re, Charrie `re, Chevalier et al., Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit, JAMA Cardiol, doi:10.1001/jamacardio.2020.1787
Bethel, Yang, Li, Nahman, Oliver et al., Hydroxychloroquine in patients with systemic lupus erythematosus with endstage renal disease, J Invest Med
Biot, Daher, Chavain, Fandeur, Khalife et al., Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, J Med Chem
Burrell, Martinez, Chloroquine and hydroxychloroquine in the treatment of cardiac arrhythmias, N Engl J Med
Cao, Wang, Wen, Liu, Wang, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med
Chatre, Roubille, Vernhet, Jorgensen, Pers, Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature, Drug Safety
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, BioSci Trends
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, Int J Antimicrob Agents
Mercuro, Yen, Shim, Maher, Mccoy et al., Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19), JAMA Cardiol, doi:10.1001/jamacardio.2020.1834
Rana, Lim, Naas, Ogston, Newton et al., QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests, Heart
Roden, Harrington, Poppas, Russo, Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment, Circulation
Simpson, Salazar, Vittinghoff, Probert, Iwahashi et al., Association of QT-prolonging medications with risk of autopsy-defined causes of sudden death, JAMA Intern Med
Teixeira, Borba, Pedrosa, Nishioka, Viana et al., Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus, Europace
Tisdale, Jaynes, Kingery, Mourad, Trujillo et al., Development and validation of a risk score to predict QT interval prolongation in hospitalized patients, Circ Cardiovasc Qual Outcomes
White, Cardiotoxicity of antimalarial drugs, Lancet Infect Dis